Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer

Open access

Abstract

Background The management of depression in patients with poor prognosis cancers, such as lung cancer, creates specific challenges. We aimed to assess the efficacy of an integrated treatment programme for major depression in patients with lung cancer compared with usual care.Methods Symptom Management Research Trials (SMaRT) Oncology-3 is a parallel-group, multicentre, randomised controlled trial. We enrolled patients with lung cancer and major depression from three cancer centres and their associated clinics in Scotland, UK. Participants were randomly assigned in a 1:1 ratio to the depression care for people with lung cancer treatment programme or usual care by a database software algorithm that used stratification (by trial centre) and minimisation (by age, sex, and cancer type) with allocation concealment. Depression care for people with lung cancer is a manualised, multicomponent collaborative care treatment that is systematically delivered by a team of cancer nurses and psychiatrists in collaboration with primary care physicians. Usual care is provided by primary care physicians. The primary outcome was depression severity (on the Symptom Checklist Depression Scale [SCL-20], range 0-4) averaged over the patient's time in the trial (up to a maximum of 32 weeks). Trial statisticians and data collection staff were masked to treatment allocation, but patients and clinicians could not be masked to the allocations. Analyses were by intention to treat. This trial is registered with Current Controlled Trials, number ISRCTN75905964.Findings 142 participants were recruited between Jan 5, 2009, and Sept 9, 2011; 68 were randomly allocated to depression care for people with lung cancer and 74 to usual care. 43 (30%) of 142 patients had died by 32 weeks, all of which were cancer-related deaths. No intervention-related serious adverse events occurred. 131 (92%) of 142 patients provided outcome data (59 in the depression care for people with lung cancer group and 72 in the usual care group) and were included in the intention-to-treat primary analysis. Average depression severity was significantly lower in patients allocated to depression care for people with lung cancer (mean score on the SCL-20 1·24 [SD 0·64]) than in those allocated to usual care (mean score 1·61 [SD 0·58]); difference -0·38 (95% CI -0·58 to -0·18); standardised mean difference -0·62 (95% CI -0·94 to -0·29). Self-rated depression improvement, anxiety, quality of life, role functioning, perceived quality of care, and proportion of patients achieving a 12-week treatment response were also significantly better in the depression care for people with lung cancer group than in the usual care group.Interpretation Our findings suggest that major depression can be treated effectively in patients with a poor prognosis cancer; integrated depression care for people with lung cancer was substantially more efficacious than was usual care. Larger trials are now needed to estimate the effectiveness and cost-effectiveness of this care programme in this patient population, and further adaptation of the treatment will be necessary to address the unmet needs of patients with major depression and even shorter life expectancy.Funding Cancer Research UK and Chief Scientist Office of the Scottish Government.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)70343-2

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 155

Metadata

Authors
Walker, J., Hansen, C. H., Martin, P., Symeonides, S., Gourley, C., Wall, L., Weller, D., Murray, G., & Sharpe, M.
Affiliations
  • Warneford Hospital (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Edinburgh (GB)
  • Western General Hospital (GB)
Corresponding author
Walker, Jane
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-09
Volume
15
Issue
10
Pages
1168-1176
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2067957872
Cited by
155
References
36
Citations by year
2026: 7 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 16 · 2018: 14 · 2017: 15 · 2016: 20 · 2015: 16 · 2014: 7
FWCI
9.34
Type
journal article
Language
en
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Edinburgh Napier Research Repository (Edinburgh Napier University) (submittedVersion)
  • Edinburgh Napier Research Repository (Edinburgh Napier University) (submittedVersion, cc-by)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
Funders
Cancer Research UK (grant numbers C5547/A7375 and C25786/A10093)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
Keywords
major depressive disorder, lung cancer, cancer-related depression, depression severity, oncology nurses, psychiatrists, primary care, usual care, poor-prognosis cancer, symptom management
MeSH terms
Age Factors, Aged, Aged, 80 and over, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, United Kingdom, Humans, Lung Neoplasms, Male, Middle Aged, Patient Care Team, Prognosis, Psychotherapy, Sex Factors, Time Factors, Comorbidity, Survival Rate, Survival Analysis, Treatment Outcome, Patient Satisfaction, Risk Assessment, Delivery of Health Care, Integrated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. https://app.cochat.ai/papers/10.1016/s1470-2045(14)70343-2
The paper
Walker, J., Hansen, C. H., Martin, P., Symeonides, S., Gourley, C., Wall, L., Weller, D., Murray, G., & Sharpe, M. (2014). Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)70343-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.